Trial Profile
Clinical Trials Insight: 700042755
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Mar 2011
Price :
$35
*
At a glance
- Drugs BCG (Primary) ; BCG (Primary) ; Epirubicin (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 22 Dec 2010 Results of this interim analysis met the criterion for statistical significance for RFS, and these results thus represented the final analysis, and the trial was terminated
- 22 Dec 2010 Status changed from active, no longer recruiting to completed.
- 22 Dec 2010 Primary endpoint 'Disease-free-survival-rate' has been met